Mannitol Polymorphs as Carrier in DPIs Formulations: Isolation Characterization and Performance.
DPI carrier
aerosolization
budesonide
in vitro toxicity
inhaler resistance
mannitol polymorphs
salbutamol sulphate
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
21 Jul 2021
21 Jul 2021
Historique:
received:
11
06
2021
revised:
16
07
2021
accepted:
19
07
2021
entrez:
28
8
2021
pubmed:
29
8
2021
medline:
29
8
2021
Statut:
epublish
Résumé
The search for best performing carriers for dry powder inhalers is getting a great deal of interest to overcome the limitations posed by lactose. The aerosolization of adhesive mixtures between a carrier and a micronized drug is strongly influenced by the carrier solid-state properties. This work aimed at crystallizing kinetically stable D-mannitol polymorphs and at investigating their aerosolization performance when used in adhesive mixtures with two model drugs (salbutamol sulphate, SS, and budesonide, BUD) using a median and median/high resistance inhaler. A further goal was to assess in vitro the cytocompatibility of the produced polymer-doped mannitol polymorphs toward two lung epithelial cell lines. Kinetically stable (up to 12 months under accelerate conditions) α, and δ mannitol forms were crystallized in the presence of 2%
Identifiants
pubmed: 34452073
pii: pharmaceutics13081113
doi: 10.3390/pharmaceutics13081113
pmc: PMC8401007
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Regione Emilia-Romagna
ID : PG/2015/731196
Références
Int J Pharm. 2011 Jun 15;411(1-2):98-105
pubmed: 21453764
Beilstein J Nanotechnol. 2014 Nov 03;5:1944-65
pubmed: 25383306
Eur J Pharm Biopharm. 2009 Jun;72(2):437-43
pubmed: 19462480
Eur J Pharm Sci. 2011 Sep 18;44(1-2):41-8
pubmed: 21699976
Int J Pharm. 2000 Nov 4;208(1-2):1-11
pubmed: 11064206
J Drug Deliv Sci Technol. 2020 Dec;60:102046
pubmed: 32905026
Expert Opin Drug Deliv. 2018 Jul;15(7):665-674
pubmed: 28829232
Int J Pharm. 2015 Jul 25;490(1-2):360-7
pubmed: 25987210
Int J Pharm. 2016 Jun 15;506(1-2):13-24
pubmed: 27094358
J Pharm Sci. 2004 Nov;93(11):2800-9
pubmed: 15368529
Int J Pharm. 2016 May 30;505(1-2):383-93
pubmed: 27090154
Acta Crystallogr C. 2003 Oct;59(Pt 10):O567-70
pubmed: 14532673
Pharm Res. 2013 Nov;30(11):2891-901
pubmed: 23893019
Int J Pharm. 2018 Aug 25;547(1-2):114-121
pubmed: 29803795
AAPS PharmSciTech. 2004 Sep 08;5(4):e60
pubmed: 15760057
Drug Dev Ind Pharm. 2009 Aug;35(8):904-16
pubmed: 19466888
Colloids Surf B Biointerfaces. 2010 Sep 1;79(2):345-56
pubmed: 20537870
Int J Pharm. 2020 Jun 15;583:119374
pubmed: 32339631
Adv Drug Deliv Rev. 2012 Mar 15;64(3):233-56
pubmed: 21616107
Bioimpacts. 2011;1(2):105-11
pubmed: 23678414
Int J Pharm. 2020 Mar 15;577:118901
pubmed: 31846726
J Pharm Sci. 1999 Feb;88(2):196-8
pubmed: 9950638
Eur Respir J. 2011 Nov;38(5):1071-80
pubmed: 21478216
J Pharm Pharmacol. 2002 Oct;54(10):1339-44
pubmed: 12396294
Pharmaceutics. 2019 Nov 04;11(11):
pubmed: 31689975
Int J Pharm. 2016 Mar 30;501(1-2):139-47
pubmed: 26851355
Int J Pharm. 2010 Dec 15;402(1-2):1-9
pubmed: 20816928
Int J Pharm. 2013 Jul 15;451(1-2):112-20
pubmed: 23643509
J Pharm Pharmacol. 2015 Jun;67(6):782-802
pubmed: 25677227
Int J Pharm. 2013 May 1;448(1):58-70
pubmed: 23500603
Am J Respir Crit Care Med. 2012 Mar 15;185(6):645-52
pubmed: 22198974
Expert Opin Drug Deliv. 2015 Jun;12(6):947-62
pubmed: 25388926
Eur J Pharm Sci. 2015 Feb 20;68:56-67
pubmed: 25497318
Int J Pharm. 2013 Oct 1;454(2):686-94
pubmed: 23747506
Eur J Pharm Sci. 2018 Feb 15;113:64-76
pubmed: 29104067
Int J Pharm. 2014 Nov 20;475(1-2):69-81
pubmed: 25151549
Int J Pharm. 2017 May 30;524(1-2):351-363
pubmed: 28347847
AAPS J. 2017 Jan;19(1):103-109
pubmed: 27631557